Dynavax Completes Enrollment Of First Cohort Of Patients In Phase 1b Clinical Trial For Hepatitis...
Dynavax Technologies Corporation (NASDAQ: DVAX) announced today that enrollment has been completed for the first of three cohorts of patients receiving DV-601 hepatitis B therapy in a Phase 1b clinical trial. The safety profile...



